Edesa director awarded 19,000 RSUs in stock grant

Chypyha Joan reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Chypyha Joan reported acquisition or exercise transactions in this Form 4 filing.

Edesa Biotech director Joan Chypyha received 19,000 common shares as a grant of restricted share units. The award was made at a stated price of $0.00 per share, reflecting compensation rather than an open-market purchase. Following this grant, Chypyha directly owns 30,029 common shares.

The restricted share units were issued under Edesa Biotech's 2019 Equity Incentive Compensation Plan and are scheduled to vest in equal portions over twelve months starting on the grant date. This represents a routine equity compensation award for a member of the board of directors.

Insider Trade Summary

Grant/Award: 19,000 shares

Grant/Award 1 txn

Insider Chypyha Joan

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Shares	19,000	$0.00	$0.00

Holdings After Transaction: Common Shares — 30,029 shares (Direct)

Footnotes (1)

1. F1. Reflects a grant of restricted share units issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan, which shall vest in equal proportions over twelve (12) months, commencing on the grant date.

Key Figures

RSU grant size: 19,000 shares Grant price: $0.00 per share Shares after transaction: 30,029 shares +2 more

5 metrics

RSU grant size 19,000 shares Restricted share units granted to director Joan Chypyha

Grant price $0.00 per share Stated price for RSU compensation grant

Shares after transaction 30,029 shares Joan Chypyha direct ownership following grant

Vesting schedule 12 months RSUs vest in equal monthly installments from grant date

Security type Common Shares Underlying security for the restricted share units

Key Terms

restricted share units, 2019 Equity Incentive Compensation Plan, vest in equal proportions, Form 4

4 terms

restricted share units financial

"Reflects a grant of restricted share units issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan"

Restricted share units (RSUs) are a promise from a company to give an employee or service provider actual shares or cash equal to the shares after certain conditions are met, typically staying with the company for a set time or hitting performance targets. Think of them like a time-locked gift card that becomes usable only after you’ve earned it. For investors, RSUs matter because they align employee incentives with company performance and can increase the number of shares outstanding over time, diluting existing ownership and affecting earnings per share.

2019 Equity Incentive Compensation Plan financial

"issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan, which shall vest in equal proportions"

vest in equal proportions financial

"which shall vest in equal proportions over twelve (12) months, commencing on the grant date"

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Edesa Biotech (EDSA) report for director Joan Chypyha?

Edesa Biotech reported a grant of 19,000 restricted share units to director Joan Chypyha. The award was priced at $0.00 per share as equity compensation, increasing her direct holdings to 30,029 common shares after the transaction.

How many Edesa Biotech (EDSA) shares does Joan Chypyha hold after the latest grant?

After receiving 19,000 restricted share units, Joan Chypyha holds 30,029 Edesa Biotech common shares directly. This total reflects the new equity award reported in the Form 4 filing and represents her post-transaction ownership position.

Was the Edesa Biotech (EDSA) Form 4 for a stock purchase or a compensation grant?

The Form 4 reflects a compensation grant, not an open-market purchase. Director Joan Chypyha received 19,000 restricted share units at a stated price of $0.00 per share under Edesa Biotech's 2019 Equity Incentive Compensation Plan.

How do the Edesa Biotech (EDSA) restricted share units granted to Joan Chypyha vest?

The 19,000 restricted share units granted to Joan Chypyha vest in equal portions over twelve months. Vesting begins on the grant date, meaning one-twelfth of the award becomes unrestricted each month during the one-year period.

What plan governed the recent Edesa Biotech (EDSA) equity award to Joan Chypyha?

The equity award was issued under Edesa Biotech's 2019 Equity Incentive Compensation Plan. Under this plan, Joan Chypyha received 19,000 restricted share units that vest monthly over twelve months, providing stock-based compensation aligned with the company’s long-term incentives.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/29/2026 - 05:01 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chypyha Joan

(Last) (First) (Middle)

C/O EDESA BIOTECH INC.

100 SPY COURT

(Street)

MARKHAM L3R 5H6

(City) (State) (Zip)

ONTARIO, CANADA

(Country)

2. Issuer Name and Ticker or Trading Symbol
Edesa Biotech, Inc. [ EDSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	05/27/2026		A		19,000(1)	A	$0(1)	30,029	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects a grant of restricted share units issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan, which shall vest in equal proportions over twelve (12) months, commencing on the grant date.

	/s/ Peter J. Weiler, Attorney-in-Fact for Joan Chypyha	05/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)